EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access

Efficacy of DaXianXiong Decoction in Preventing the Progression of Acute Pancreatitis Severity: Protocol for a Randomized Controlled Trial

Dongsheng Ren iD, Judan Tan iD, Yuling Zhou iD, Zhenchun Luo iD

JMIR Research Protocols · 2025

DOI: 10.2196/67392 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JMIR Research Protocols, 2025. Verfasst von Dongsheng Ren und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency and Intensive Critical Unit, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Pancreatitis. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Low- and middle-income countries are facing an increase in the incidence of acute pancreatitis (AP)—characterized by rapid onset, fast progression, high rate of severity, and high mortality. Progression of AP into severe AP (SAP) results in a series of complications such as organ dysfunction, local abscesses, pseudocysts, and necrosis. Although the treatment of AP is primarily supportive, including fluid resuscitation and organ support, there is still a lack of consensus on the optimal management regimen for fluid therapy, and strategies to promote gastrointestinal recovery remain limited. As no effective intervention measure has yet been developed, supportive therapy remains the primary approach for the early treatment of AP. DaXianXiong decoction is a widely used traditional Chinese medicine formulation; however, limited research has been conducted on its clinical efficacy.

Objective

This study aims to evaluate the efficacy and safety of DaXianXiong decoction in preventing AP from progressing to SAP, assessing its impact on SAP incidence, clinical severity scores, inflammation markers, and gastrointestinal function, and providing evidence for AP management.

Methods

This study is a randomized, double-blind, placebo-controlled, single-center clinical trial. The primary outcomes will include the incidence of SAP, modified computed tomography severity index score, APACHE II (Acute Physiology and Chronic Health Evaluation II) score, modified Marshall score, and levels of the inflammation factor. The secondary outcomes will include the effect of the gastrointestinal dysfunction treatment. Evaluations will be conducted at baseline; 24 hours after the intervention; and on days 3, 7, and 28 after the intervention in both groups. A total of 60 eligible patients will be randomly allocated in a 1:1 ratio to the intervention group and the control group. Both groups will receive standard Western medical treatment for pancreatitis. The intervention group will additionally receive DaXianXiong decoction, while the control group will receive a placebo similar to the decoction.

Results

This study has been funded by the Performance Incentive Project of Scientific Research Institutions in Chongqing. The trial was registered in April 2024, and data analysis is expected to be completed by April 2025. The study results will be presented at both national and international conferences and published in peer-reviewed journals.

Conclusions

This trial will help us assess the effectiveness and safety of DaXianXiong decoction in patients with AP and provide clinical evidence on the efficacy and safety of DaXianXiong decoction in preventing the progression of AP to SAP. By evaluating its impact, the findings will contribute to the understanding of DaXianXiong decoction as an adjunct therapy in AP management and may offer a novel complementary treatment strategy for AP, potentially improving patient outcomes and reducing complications. Trial Registration Chinese Clinical Trial Registry ChiCTR2300076885; https://www.chictr.org.cn/showproj.html?proj=207084 International Registered Report Identifier (IRRID) DERR1-10.2196/67392

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drugs, Chinese HerbalPancreatitisHumansDisease ProgressionDouble-Blind MethodSeverity of Illness IndexRandomized Controlled Trials as TopicMaleAdultFemaleTreatment OutcomeMiddle AgedAcute DiseaseMedicine, Chinese Traditional

Stichwörter der Autor:innen

acute pancreatitispreventprotocolsevere acute pancreatitistraditional Chinese medicine

Substanzen

Drugs, Chinese Herbal

Autor:innen und Institutionen

  • Department of Emergency and Intensive Critical Unit, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.

ORCID-Profile: Dongsheng Ren, Judan Tan, Yuling Zhou, Zhenchun Luo

Zitieren

APA

Ren, D., Tan, J., Zhou, Y., & Luo, Z. (2025). Efficacy of DaXianXiong Decoction in Preventing the Progression of Acute Pancreatitis Severity: Protocol for a Randomized Controlled Trial. JMIR Research Protocols. https://doi.org/10.2196/67392

Vancouver

Ren D, Tan J, Zhou Y, Luo Z. Efficacy of DaXianXiong Decoction in Preventing the Progression of Acute Pancreatitis Severity: Protocol for a Randomized Controlled Trial. JMIR Research Protocols. 2025. doi:10.2196/67392

BibTeX
@article{Ren2025,
  author = {Ren, Dongsheng and Tan, Judan and Zhou, Yuling and Luo, Zhenchun},
  title = {Efficacy of DaXianXiong Decoction in Preventing the Progression of Acute Pancreatitis Severity: Protocol for a Randomized Controlled Trial},
  journal = {JMIR Research Protocols},
  year = {2025},
  doi = {10.2196/67392}
}
Kostenlos starten →